{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:47:01Z","timestamp":1775072821785,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/inf.0000000000001399","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T18:27:07Z","timestamp":1478975227000},"page":"216-223","source":"Crossref","is-referenced-by-count":39,"title":["Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains"],"prefix":"10.1097","volume":"36","author":[{"given":"Shannon L.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G. K.","family":"Donald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Cesar","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210202","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R2-18-20210202","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"R3-18-20210202","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"R4-18-20210202","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease.","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"R8-18-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"R14-18-20210202","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"R15-18-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"R16-18-20210202","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"R17-18-20210202","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase \u00bd trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R19-18-20210202","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"R21-18-20210202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease.","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R25-18-20210202","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R27-18-20210202","first-page":"289","article-title":"Serogroup B and C serum bactericidal assays.","volume":"66","author":"Borrow","year":"2001","journal-title":"Methods Mol Med"},{"key":"R28-18-20210202","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"R31-18-20210202","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R34-18-20210202","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/hv.18500","article-title":"Bexsero: a multicomponent vaccine for prevention of meningococcal disease.","volume":"8","author":"Gorringe","year":"2012","journal-title":"Hum Vaccin Immunother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:58Z","timestamp":1620954778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201702000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001399","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}